Allergy Therapeutics Share Discussion Threads

[totally banjo] 19/12/2024 13:18

Part from an article today:

Allergy Therapeutics: A story of resilience and transformation
Published: 12:32 19 Dec 2024 GMT

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) is writing a story of resilience and transformation. Putting behind it manufacturing setbacks, the company has redefined its trajectory with a bold strategy centred on innovation.

Its pioneering short-course therapies, designed to tackle conditions such as hay fever and peanut allergy, promise not only to disrupt traditional treatments but to drive significant growth and value in the process.

Its August results hinted at a turning point. In the second half of the financial year, the company posted its first revenue growth since 2021, a milestone that signals progress but also serves as a prelude to something potentially transformative.

That journey has already begun with the Grass MATA MPL treatment - for grass pollen allergies - which late last month was submitted for regulatory approval in Germany. If greenlit by the Paul-Ehrlich-Institut (PEI), the treatment could be on the market by this time next year.

“We have worked around the clock to get the trading business back to growth,” says CEO Manuel Llobet.

“The Peanut project is very exciting, but maybe in the short term, more interestingly, is the regulatory submission we have made [for Grass MATA MPL], where the primary endpoint was met.”

Strong balance sheet

More recently, Allergy Therapeutics has strengthened its financial position with a new £40 million debt line from Hayfin Healthcare Opportunities, comprising a £20 million committed five-year term loan and a £20 million uncommitted incremental facility. Additionally, it has increased an existing loan facility by £10 million to £50 million.

This sort of backing suggests Allergy Therapeutics may be onto something big, an assertion supported by analysts at the research house Cavendish.

Using a discounted cash flow model, they have set a price target of 13p for stock in Allergy Therapeutics - a 124% premium to the current share price.

Specifically, the Cavendish number crunchers believe VLP Peanut could achieve blockbuster status in the US with annual sales in excess of $1 billion, while it expects a not-insubstantial $300–400 million peak sales from Grass MATA MPL.

Cavendish is also predicting strong top-line growth to the previously sedentary existing commercial operation and believes the company’s technology provides a strong moat (Warren Buffett’s term for competitive protection) to the business.

Summarising the 37-page research ‘opus’, Cavendish said it believes Allergy Therapeutics has the ability, based on its two key assets, to generate “significant potential future value for shareholders”.

[totally banjo] 19/12/2024 13:11

Hi beccasan, were you that excited with your offering that you felt the need to duplicate your post? :-)

[beccasan] 19/12/2024 10:09

Lots of communication from Allergy Therapeutics, about lots of unimportant things. Promises, hot air, too bad they forgot to communicate that they are effectively out of the Italian market because essentially the regulatory body does not believe in these products.
hxxps://www.aifa.gov.it/en/-/determina-dts-115/2024-cessazione-del-periodo-di-continuità-terapeutica-medicinali-allergeni-

[jimmyloser] 18/12/2024 11:57

This really pleases me to see this approach to key workers.Thanks for highlighting it Banjo

[totally banjo] 18/12/2024 11:25

Yesterdays announcement Re 'Block Listing Interim Review' relates to one of the resolutions passed the day before at the AGM:

Approval of Special Awards

The Company is seeking approval from the Shareholders to authorise the Directors to finalise and implement arrangements for the grant of the special, out of cycle, long term incentive awards to the Company's senior executive team (the "LTIP Awards") and additional option awards to the Company's employees (the "Option Awards" and, together with the LTIP Awards, the "Special Awards").

The LTIP Awards are intended to incentivise and reward extraordinary levels of share price growth and shareholder value creation over a five-year period, as more patients benefit from the Company's immunotherapies. The remuneration committee of the Company believes that the mix of remuneration awards will ensure a balance between strong growth and reaching for full potential.

In order to make the Special Awards, the Company needs to make certain amendments to its 2023 Long Term Share Incentive Plan (the "Plan") and to adopt a sub-plan to the Plan. No amendments will be made to the overall Plan limit. The maximum aggregate number of ordinary shares under option pursuant to the LTIP Awards will be approximately 215 million, representing 4.5% of the Company's issued share capital as at 14 November 2024. The Company anticipates that the Option Awards will in aggregate be granted over a maximum of 1.7% of the Company's issued share capital as at 14 November 2024.

[totally banjo] 17/12/2024 12:18

I missed that yesterday,as expected all resolutions passed at the AGM.

[totally banjo] 16/12/2024 17:10

Nice finish for the day 😀

[totally banjo] 12/12/2024 17:14

Looking good!

Edit-It was showing 6.3 at 17:30!

[jpuff] 12/12/2024 10:47

Should think so as shorting the market particularly AIM has been vastly more profitable than investing these past five years. No wonder companies are queuing up to quit the London market to cross the pond!

[jimmyloser] 12/12/2024 09:33

I should think so, mm's showing the Christmas spirit.Hohoho

[totally banjo] 10/12/2024 00:09

Cheers jimmy, spent a bit of time this afternoon (rather than going out working in cold) sorting all the information out regarding the Grass MATA MPL time frame.

Got beat 8-1 at darts tonight but pool on Wednesday which we are much better at, should be good and potentially project us to top of league!

[jimmyloser] 09/12/2024 18:10

Banjo nice post.

One only has to look at the graph above to feel (and see) that we are headed in the right direction.

I am happier than I have been for a long time.

[totally banjo] 09/12/2024 14:44

Grass MATA MPL immunotherapy vaccine completed the G309 and G306 studies which included people/subjects from the USA along with the USA relevant regulators being closely involved, which assists in the application for FDA (USA approval) further down the road.

I believe the statement "Concurrently, we are exploring US registration opportunities" will be for the initial G307 study involving just USA subjects before the FDA route can commence.

Grass MATA MPL immunotherapy vaccine started the Marketing Authorisation Application for Germany 25th Nov 2024 via the Paul Ehrlich Institute (PEI) and if successful paves the way for sales in the largest market in Europe!

There's still a way to go but if AGY keep reporting positive news and results it all adds up in giving the share price a firm foundation for further rises, in my humble opinion of course!

[jimmyloser] 09/12/2024 08:01

Talk about out of the traps like a rocket. lol

[jimmyloser] 06/12/2024 17:17

That is encouraging to know Coin.Thanks

[coinbase] 06/12/2024 17:04

The bid was absolutely stacked in the post market auction.

[totally banjo] 06/12/2024 14:03

That's relating to the Grass MATA vaccine isn't it, having a break from hedge cutting so just assuming?

[jimmyloser] 06/12/2024 13:51

Could this be our next piece of news or how about them releasing an upbeat AGM statement now that they finally can?


6/11/2024
Concurrently, we are exploring US registration opportunities, with plans to engage with the FDA regarding the clinical programme to meet US requirements.

impo

[totally banjo] 06/12/2024 10:29

Hi sleveen, I wasn't trying to mislead!

That is the goal of the vaccine but obviously it all depends on the outcome of the PROTECT trial in USA.

[jimmyloser] 06/12/2024 10:09

Hence the amount of money that has been poured into it methinks.

Now you can get 5.6p to sell.

[jpuff] 05/12/2024 21:50

Looks like a inverse head and shoulders formation which bodes well. Maybe Santa will give us a pleasant surprise this year?

[jpuff] 05/12/2024 21:47

That's a movement I do like after the respective doses of both sennacot and caster oil.

[totally banjo] 05/12/2024 20:11

Well that did the trick! :-)

[jimmyloser] 05/12/2024 14:07

What the bid price needs is a good dose of Caster Oil to get it moving!Let's see if that works.